Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
212 hedge funds and large institutions have $2.12B invested in Portola Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 92 increasing their positions, 46 reducing their positions, and 26 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 46
42% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 26
10% more capital invested
Capital invested by funds: $1.92B → $2.12B (+$201M)
5% more funds holding
Funds holding: 202 → 212 (+10)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
51% less call options, than puts
Call options by funds: $9.14M | Put options by funds: $18.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$52.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$34.1M |
| 3 |
BlackRock
New York
|
+$25.1M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$21.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$17.4M |
| 2 |
CCM
Cadian Capital Management
New York
|
-$11.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.8M |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$10.5M |
| 5 |
Morgan Stanley
New York
|
-$7.67M |
PTLA Hedge Fund Activity: Q3 2019 in Review
212 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2019, worth a combined $2.12B — up 10% from $1.92B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new PTLA positions and 26 closed out — a net gain of 11 holders — while 92 added to existing stakes and 46 trimmed.
The largest buyer was William Blair Investment Management, adding an estimated $52.3M. The largest seller was JP Morgan Chase, cutting an estimated $17.4M.
- 212 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2019, up from 202 in Q2 2019.
- Funds reported $2.12B of Portola Pharmaceuticals, Inc. stock for Q3 2019, up 10% quarter-over-quarter.
- 37 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2019 and 26 closed out, a net change of +11 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q3 2019 was William Blair Investment Management, an estimated $52.3M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q3 2019 was JP Morgan Chase, an estimated $17.4M sold.
Based on aggregated 13F filings for Q3 2019.